What are BD's primary business segments and what do they offer?

Becton, Dickinson and Company (BDX) operates in three principal segments: BD Medical, which offers a broad array of medical devices like safety-engineered injection and infusion products; BD Diagnostics, providing products for safe specimen collection and instrumentation for infectious disease testing; and BD Biosciences, which produces research and clinical tools for cell analysis and drug discovery.

What are the key strategic initiatives or developments mentioned in the filing?

Key strategic developments include the acquisition of GeneOhm Sciences to bolster its healthcare-associated infection diagnostics, the agreement to acquire TriPath Imaging to enhance cancer diagnostics, and the decision to exit the blood glucose monitoring market. These moves indicate a strategic focus on high-growth areas and portfolio optimization.

What are the major risks or legal proceedings highlighted in the report?

BDX faces significant risks including intense competition in the medical technology market, potential disruptions in raw material supply, product defects, regulatory compliance challenges (including a recent FDA warning letter for a Puerto Rico facility), and foreign currency exchange rate fluctuations due to its substantial international operations. Additionally, the company is a defendant in several antitrust and product liability lawsuits, which could result in material financial impacts.

How is BDX investing in future growth?

BDX is investing heavily in Research and Development, with expenditures of $360 million in fiscal year 2006, to drive innovation and develop new products across its segments. The company also pursues strategic acquisitions to complement its internal growth strategies.

BDX 10-K FY2006 Annual Report — Revenue, Net Income, EPS

Summary

Becton, Dickinson and Company (BDX) reported its fiscal year ended September 30, 2006, highlighting its position as a leading medical technology company. The company operates across three primary segments: Medical, Diagnostics, and Biosciences, offering a diverse range of products and solutions for healthcare institutions, life science researchers, and clinical laboratories worldwide. BDX has strategically focused on growth through both internal development and acquisitions. Notable strategic moves in the reported period include the acquisition of GeneOhm Sciences, Inc., expanding its presence in healthcare-associated infection diagnostics, and the announced agreement to acquire TriPath Imaging, strengthening its cancer diagnostic offerings. The company also announced its exit from the blood glucose monitoring market, signaling a reallocation of resources. With a significant international presence, BDX navigates global economic conditions and currency fluctuations, while also addressing regulatory landscapes and competitive pressures inherent in the medical technology sector.

Key Highlights

1BDX operates through three distinct global segments: Medical, Diagnostics, and Biosciences, catering to a wide array of healthcare and research needs.
2Strategic acquisitions, including GeneOhm Sciences and the pending acquisition of TriPath Imaging, indicate a focus on expanding capabilities in diagnostics and disease management.
3The company is exiting the blood glucose monitoring market, suggesting a strategic shift away from certain product lines.
4BDX has a substantial international footprint, with manufacturing and sales operations across numerous countries, though this also exposes it to foreign currency exchange risks.
5Significant investment in Research and Development ($360 million in fiscal year 2006) underscores a commitment to innovation and new product development.
6The company is facing multiple antitrust lawsuits related to its products, which represent a notable legal risk.
7BDX reported effective disclosure controls and procedures, with management affirming their effectiveness as of September 30, 2006.

BECTON DICKINSON & CO Annual Report, Year Ended Sep 30, 2006

Summary

Key Highlights

Frequently Asked Questions